Categories

What is Therapeutic Antibody Discovery and Why is it Important? Antibody therapeutics have tremendous research and clinical value having the potential to combat different diseases such as cancers, HIV, autoimmune, hereditary, and more. The technologies used to discover these antibody-based…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Pavel Ryzhov, Field Application Scientist Came aboard: April 2022 What do you do at Telesis Bio? I work with…

Since Köhler and Milstein first succeeded in fusing myeloma cell lines with B cells to create hybridomas in 1975,1 antibodies have become well-established therapeutics. With advantages relative to selectivity, effector function, and bioavailability over small molecule drugs, antibody therapeutics are…

Cellular therapy research is booming with applications in cancer and further innovations on the horizon for infectious, autoimmune, and chronic inflammatory diseases. The progression in understanding the tumor microenvironment and how the immune cells infiltrate and kill tumor cells has…

Laurence Warden, Senior Vice President, Engineering and Instrumentation, led his team to develop the BioXp® 9600 system – a high-throughput benchtop platform for synthetic biology workflows designed to empower scientists to accelerate the discovery of new vaccines and biologics. Read…

Introducing the Next Generation Automated Synthetic Biology Workstation Telesis Bio recently announced the commercial release of the BioXp® 9600 system – a fully automated, high-throughput benchtop platform for synthetic biology workflows designed to empower scientists to accelerate discovery of new…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Silvio Cenzi, Senior Manager, Field Service Field Support Came aboard: January 10, 2022 What do you do at Telesis…

Ben Chiarelli, Founder and CEO of Cellibre, a company revolutionizing agricultural manufacturing, discussed the company’s goal of shortening their complex design-build-test process to produce globally significant products at scale. Ben also shared how the partnership with Telesis Bio empowered their…

We caught up with Jason Lehmann, Senior Product Marketing Manager at Telesis Bio, as he shares how our synthetic biology workstation, the BioXp® system, can accelerate your time to results by optimizing production workflows and overcoming synthesis bottlenecks. How do…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Ken Williams, Bioinformatics Scientist Lead Came aboard: February 2020 What do you do at Telesis Bio? I develop the…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Sydney Kerr, Senior Research Associate Came aboard: January 2021 What do you do at Telesis Bio? I work on…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Michelle Vargas, Scientist Came aboard: March 2021 What do you do at Telesis Bio? I work on the Research…

Built with Biology (Formerly SynBioBeta) hosted its global synthetic biology conference in Oakland, CA last week. The conference brought together synthetic biology’s leading community of innovators, investors, and thought leaders to collaborate in solving our world’s biggest problems through biology.…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: John Gill, Senior Director of Research and Development Came aboard: April 2020 What do you do at Telesis Bio?…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Elijah Grote, Software Engineer Came aboard: November 2020. What do you do at Telesis Bio? I add features and…

On Monday, January 24th, NBC 7 San Diego reporter Madison Weil interviewed Telesis Bio’s CEO, Todd Nelson, to discuss our recent early access collaboration and licensing agreement with Pfizer. Under this agreement, Pfizer gains early access to Telesis Bio’s proprietary…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Yanming Gong, Director of Synthesis Came aboard: September 2021. What do you do at Telesis Bio? I work in…

We’re proud of Telesis Bio’s Co-Founder and CTO, Dan Gibson, for being featured in this year’s Newsweek Magazine’s America’s Greatest Disruptor list. With his team of scientists at Telesis Bio, Dan Gibson is focused on creating a new paradigm for…

Telesis Bio’s mission is to drive innovation and apply breakthroughs in automation solutions for DNA, mRNA, and protein synthesis. These tools enable scientists to “write” biology for the betterment of the world, creating sustainable healthcare and technology solutions for humanity’s…

It’s been one year since we launched the BioXp® 3250 system — our fully automated biology for gene synthesis, cloning, mRNA synthesis, variant DNA libraries, and more — and we’re excited to see how much progress researchers have made with…

The Discovery on Target 2021 conference took place Sept 28-30 in Boston, bringing together several experts from across the US and globally to foster collaboration and share the latest advances in addressing key challenges in drug discovery. At this year’s…

Across the life sciences, researchers have contributed significantly to the response to COVID-19 — elucidating the pathogen, tracking the progression and consequences of infection, and uncovering many of the biological mechanisms associated with patients who display symptoms for months or…

Synthetic biology has become so important and widely used that it’s easy to forget how young the field is. Much of the innovation that we rely on today took place in just the last two decades. Telesis Bio was originally…

Team member: Gary Mills, Director of Software Engineering What do you do at Telesis Bio? I work on the BioXp® system, both the 3200 and 3250. My team works on the software and scripting that run the protocols for the…

If you’re working with synthetic mRNA, we have exciting news to share. In addition to releasing a new workflow earlier this year that makes it possible to synthesize mRNA form pooled oligos in a single overnight run on our BioXp®…

Our BioXp® automated end-to-end benchtop system has been used by scientists in many different focus areas to advance breakthroughs in protein engineering. We are delighted to share a great example of utilizing BioXp gene and clone workflows to build recombinant…

RNA Day is on Sunday, August 1st this year, and we welcome the international celebration of one of the most versatile biomolecules we have seen come to life. We have seen RNA play a key role in addressing the COVID-19…

We’re thrilled to announce the partnership with MBC Biolabs, a premier biotech incubator in the Bay Area. Under the terms of the collaboration, MBC Biolabs will leverage Telesis Bio’s BioXp® system to empower entrepreneurs in life sciences research with the…

In San Diego, scientists at ag biotech startup Cellibre are looking to replace traditional agriculture for producing high-value ingredients. One of their first targets is the highly valuable cannabinoid market, which they believe can be disrupted by producing natural, high-quality,…

Scientists use automated DNA synthesis to identify regulatory mechanism in E. coli response to antimicrobial threats. Bacterial resistance to antibiotics is a looming public health crisis, and scientists continue to investigate how to better characterize the molecular mechanisms underpinning this…

The bacterial scourge of the citrus greening disease has affected citrus production worldwide, causing tree decline and a serious threat to Florida’s citrus industry. Citrus greening disease, or Huanglongbing (HLB), is caused by Candidotus liberibacter (CLass) and is spread by…

The quest for an effective vaccine against HIV has spanned decades. While the vaccine itself remains elusive, researchers are making important strides in figuring out how best to design and develop it. Recently, scientists from Duke University and NIH’s Vaccine…

Scientists have made a new discovery that could eventually lead to more effective treatment for malaria. In a series of experiments that included using the BioXp® system, they determined that a key phospholipid and a related protein confer protection against…

Monoclonal antibodies represent an important class of therapies for an ever-increasing number of diseases, infections, and health conditions. That’s why scientists around the world are working to improve the processes required to engineer new antibody candidates for therapeutic use. The…

Since the start of the COVID-19 pandemic, the Telesis Bio team has been working hard to ensure that our customers have access to the tools they need to help in the fight against this public health scourge. We currently offer…

At a recent Oxford Global NextGen Omics UK congress, our own Kirsty Maclean gave a presentation about how the BioXp® system is powering advances in cell engineering. While she started with a high-level view of how synthetic biology applies to…

You probably know Telesis Bio as the developer of the world’s first and only automated benchtop solution for generating gene fragments, clones, and libraries. While we’re incredibly proud of what we’ve accomplished so far, our mission goes well beyond streamlining…

There’s celebrating in the halls — and virtual halls — of Telesis Bio. We are truly honored that our new BioXp® 3250 system was selected as one of the year’s best innovations by The Scientist. This is a very prestigious…

Back in 2013, I played a small role in response to what then seemed like the next potential pandemic — an outbreak of H7N9, an avian influenza virus. At the time, I was working with Novartis scientists, and we were…

In the age of COVID-19, there has been a ton of scientific interest in nanobodies, or single-domain antibodies that can be used for finely targeted viral vaccines. It’s also been a hot topic among users of our BioXp® system —…

Without question, the global outbreak of the novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 has dominated scientific discussion and has been fodder for a wealth of publications as the world urgently races for a better understanding of the mechanism of…

Breast cancer is now recognized as the most common malignancy worldwide among women, irrespective of age. Today’s standard of care and breast cancer management relies heavily on chemotherapy, hormone therapy, and targeted therapy. However, there is still much to be…

The Telesis Bio team really enjoyed attending this year’s virtual Global Synthetic Biology Conference hosted by SynBioBeta. If you missed the event, we’ve got you covered — here’s our take on highlights from the meeting. BioXp® system in the spotlight…

The treatment landscape for lymphoma – especially aggressive B-cell lymphomas — has been transformed by adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells. Clinical trials with a focus on anti-CD19 CAR-T cell therapy have shown efficacy and long-term…

Please join us in welcoming the newest member of the Telesis Bio family. Like its BioXp® 3200 predecessor, the BioXp® 3250 system is a fully automated, benchtop platform for synthetic biology workflows — but this one reduces the timelines for…